Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free ARTL Stock Alerts

Artelo Biosciences (ARTL) Competitors

Artelo Biosciences logo
$1.16 +0.11 (+10.48%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$1.16 +0.00 (+0.09%)
As of 07/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ARTL vs. VTGN, MTEX, CVKD, BON, and APRE

Should you buy Artelo Biosciences stock or one of its competitors? MarketBeat compares Artelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artelo Biosciences include VistaGen Therapeutics (VTGN), Mannatech (MTEX), Cadrenal Therapeutics (CVKD), Bon Natural Life (BON), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry.

How does Artelo Biosciences compare to VistaGen Therapeutics?

Artelo Biosciences (NASDAQ:ARTL) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Artelo Biosciences has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$32.74N/A
VistaGen Therapeutics$1.27M7.95-$69.68M-$1.83N/A

Artelo Biosciences currently has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 286.02%. Given Artelo Biosciences' higher probable upside, research analysts plainly believe Artelo Biosciences is more favorable than VistaGen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
VistaGen Therapeutics
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Artelo Biosciences had 3 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 5 mentions for Artelo Biosciences and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.93 beat Artelo Biosciences' score of 0.02 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artelo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
VistaGen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Artelo Biosciences has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Artelo Biosciences has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -1,600.12% -224.62%
VistaGen Therapeutics -5,487.01%-133.02%-105.79%

Summary

VistaGen Therapeutics beats Artelo Biosciences on 8 of the 14 factors compared between the two stocks.

How does Artelo Biosciences compare to Mannatech?

Artelo Biosciences (NASDAQ:ARTL) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Artelo Biosciences has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Artelo Biosciences' return on equity of -1,600.12% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -1,600.12% -224.62%
Mannatech -11.97%-2,383.34%-40.24%

Artelo Biosciences currently has a consensus target price of $54.00, indicating a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Mannatech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Artelo Biosciences had 2 more articles in the media than Mannatech. MarketBeat recorded 5 mentions for Artelo Biosciences and 3 mentions for Mannatech. Mannatech's average media sentiment score of 1.29 beat Artelo Biosciences' score of 0.02 indicating that Mannatech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artelo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Mannatech
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Artelo Biosciences has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$32.74N/A
Mannatech$108.04M0.08-$15.21M-$6.71N/A

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Artelo Biosciences has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Summary

Artelo Biosciences and Mannatech tied by winning 7 of the 14 factors compared between the two stocks.

How does Artelo Biosciences compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Cadrenal Therapeutics' return on equity of -411.03% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cadrenal TherapeuticsN/A -411.03% -275.61%
Artelo Biosciences N/A -1,600.12%-224.62%

Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cadrenal TherapeuticsN/AN/A-$13.24M-$5.63N/A
Artelo BiosciencesN/AN/A-$12.88M-$32.74N/A

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 437.19%. Artelo Biosciences has a consensus price target of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Cadrenal Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadrenal Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Cadrenal Therapeutics and Cadrenal Therapeutics both had 5 articles in the media. Cadrenal Therapeutics' average media sentiment score of 0.89 beat Artelo Biosciences' score of 0.02 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cadrenal Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Artelo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Cadrenal Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 26.1% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cadrenal Therapeutics beats Artelo Biosciences on 8 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Bon Natural Life?

Artelo Biosciences (NASDAQ:ARTL) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Bon Natural Life has higher revenue and earnings than Artelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$32.74N/A
Bon Natural Life$18.67M0.51-$2MN/AN/A

In the previous week, Artelo Biosciences had 3 more articles in the media than Bon Natural Life. MarketBeat recorded 5 mentions for Artelo Biosciences and 2 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.59 beat Artelo Biosciences' score of 0.02 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artelo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Bon Natural Life
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Artelo Biosciences currently has a consensus target price of $54.00, suggesting a potential upside of 4,555.17%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Artelo Biosciences is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bon Natural Life's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -1,600.12% -224.62%
Bon Natural Life N/A N/A N/A

Artelo Biosciences has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

Summary

Bon Natural Life beats Artelo Biosciences on 6 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to Aprea Therapeutics?

Artelo Biosciences (NASDAQ:ARTL) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Aprea Therapeutics has higher revenue and earnings than Artelo Biosciences. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artelo BiosciencesN/AN/A-$12.88M-$32.74N/A
Aprea Therapeutics$290K31.10-$12.60M-$1.54N/A

Artelo Biosciences has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Artelo BiosciencesN/A -1,600.12% -224.62%
Aprea Therapeutics -4,405.59%-61.03%-50.24%

Artelo Biosciences has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Artelo Biosciences had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Artelo Biosciences and 2 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.93 beat Artelo Biosciences' score of 0.02 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Artelo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Aprea Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Artelo Biosciences presently has a consensus price target of $54.00, indicating a potential upside of 4,555.17%. Aprea Therapeutics has a consensus price target of $4.07, indicating a potential upside of 458.30%. Given Artelo Biosciences' higher possible upside, research analysts clearly believe Artelo Biosciences is more favorable than Aprea Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Aprea Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aprea Therapeutics beats Artelo Biosciences on 11 of the 15 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTL vs. The Competition

Export
MetricArtelo BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.45M$3.68B$6.86B$12.44B
Dividend YieldN/A2.19%2.68%8.42%
P/E Ratio-0.0420.9827.0124.38
Price / SalesN/A311.10522.3491.89
Price / CashN/A143.6648.5959.36
Price / Book-0.618.5410.806.33
Net Income-$12.88M$23.83M$3.59B$331.02M
7 Day Performance16.43%-2.77%-1.49%-0.33%
1 Month Performance-10.77%5.85%2.79%-1.29%
1 Year Performance-97.59%52.15%28.56%21.30%

Artelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTL
Artelo Biosciences
1.3559 of 5 stars		$1.16
+10.5%		$54.00
+4,555.2%		-97.9%$2.45MN/AN/A5
VTGN
VistaGen Therapeutics
2.7991 of 5 stars		$0.24
-3.6%		$0.95
+301.0%		-89.7%$10.09M$1.27MN/A40
MTEX
Mannatech
1.6985 of 5 stars		$5.25
+4.2%		N/A-45.2%$9.73M$108.04MN/A250
CVKD
Cadrenal Therapeutics
2.8802 of 5 stars		$3.16
-6.0%		$13.00
+311.4%		-80.6%$9.64MN/AN/A4
BON
Bon Natural Life
1.2298 of 5 stars		$1.17
-0.8%		N/A-23.9%$9.59M$18.67MN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Hidden on Tesla's filing: A $12 billion "super startup"
Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...
Banyan Hill Publishing | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel